Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people

Si, Jiahui; Yu, Canqing; Guo, Yu; Zheng, Bin; Meng, Ruogu; Yang, Ling; Jin, Jianrong; Liu, Jingchao; Guo, Ziyan; Chen, Junshi; Chen, Zhengming; Lv, Jun; Li, Liming

doi:10.1136/bmjopen-2018-027696

Cited by 30 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HBV represents a threat to global health and accounts for more than 880,000 deaths each year due to complications [ 121 ]. Over 250 million people worldwide are chronic carriers of this virus.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Virus Entry into Cells

Herrscher

Roingeard

Blanchard

2020

Cells

View full text Add to dashboard Cite

Hepatitis B virus (HBV), an enveloped partially double-stranded DNA virus, is a widespread human pathogen responsible for more than 250 million chronic infections worldwide. Current therapeutic strategies cannot eradicate HBV due to the persistence of the viral genome in a special DNA structure (covalently closed circular DNA, cccDNA). The identification of sodium taurocholate co-transporting polypeptide (NTCP) as an entry receptor for both HBV and its satellite virus hepatitis delta virus (HDV) has led to great advances in our understanding of the life cycle of HBV, including the early steps of infection in particular. However, the mechanisms of HBV internalization and the host factors involved in this uptake remain unclear. Improvements in our understanding of HBV entry would facilitate the design of new therapeutic approaches targeting this stage and preventing the de novo infection of naïve hepatocytes. In this review, we provide an overview of current knowledge about the process of HBV internalization into cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B Virus Entry into Cells

Herrscher

Roingeard

Blanchard

2020

Cells

View full text Add to dashboard Cite

show abstract

“…HBV infection is one of the most critical universal public health burdens [ 62 ]. According to global estimates over one-third of the World’s population have been diseased with HBV, and about 5% of this population are infected recurrently and around 25 % of these chronic carriers have severe liver diseases like cirrhosis, hepatic carcinoma, and chronic hepatitis [ 63 ].…”

Section: Selective Adhesion On Fet For Biosensing Applicationsmentioning

confidence: 99%

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Sadighbayan

Hasanzadeh

Ghafar-Zadeh

2020

TrAC Trends in Analytical Chemistry

156

View full text Add to dashboard Cite

The use of field-Effect-Transistor (FET) type biosensing arrangements has been highlighted by researchers in the field of early biomarker detection and drug screening. Their non-metalized gate dielectrics that are exposed to an electrolyte solution cover the semiconductor material and actively transduce the biological changes on the surface. The efficiency of these novel devices in detecting different biomolecular analytes in a real-time, highly precise, specific, and label-free manner has been validated by numerous research studies. Considerable progress has been attained in designing FET devices, especially for biomedical diagnosis and cell-based assays in the past few decades. The exceptional electronic properties, compactness, and scalability of these novel tools are very desirable for designing rapid, label-free, and mass detection of biomolecules. With the incorporation of nanotechnology, the performance of biosensors based on FET boosts significantly, particularly, employment of nanomaterials such as graphene, metal nanoparticles, single and multi-walled carbon nanotubes, nanorods, and nanowires. Besides, their commercial availability, and high-quality production on a large-scale, turn them to be one of the most preferred sensing and screening platforms. This review presents the basic structural setup and working principle of different types of FET devices. We also focused on the latest progression regarding the use of FET biosensors for the recognition of viruses such as, recently emerged COVID-19, Influenza, Hepatitis B Virus, protein biomarkers, nucleic acids, bacteria, cells, and various ions. Additionally, an outline of the development of FET sensors for investigations related to drug development and the cellular investigation is also presented. Some technical strategies for enhancing the sensitivity and selectivity of detection in these devices are addressed as well. However, there are still certain challenges which are remained unaddressed concerning the performance and clinical use of transistor-based point-of-care (POC) instruments; accordingly, expectations about their future improvement for biosensing and cellular studies are argued at the end of this review.

show abstract

“…As reviewed elsewhere, sexually transmitted viruses, like HSV-2, HPV, cytomegalovirus (CMV), hepatitis B or HIV, have been associated with a range of adverse health outcomes [66][67][68][69][70][71], including cervical cancer (HPV) [66], genital ulcers (HSV-2), aseptic meningitis as well as vertical infections in infants, such as neonatal herpes (HSV-2) [67] or cirrhosis and liver cancer (hepatitis B) [69,70].…”

Section: Eukaryotic-infecting Virusesmentioning

confidence: 99%

The Vaginal Virome—Balancing Female Genital Tract Bacteriome, Mucosal Immunity, and Sexual and Reproductive Health Outcomes?

Happel

Varsani

Balle

et al. 2020

Viruses

View full text Add to dashboard Cite

Besides bacteria, fungi, protists and archaea, the vaginal ecosystem also contains a range of prokaryote- and eukaryote-infecting viruses, which are collectively referred to as the “virome”. Despite its well-described role in the gut and other environmental niches, the vaginal virome remains understudied. With a focus on sexual and reproductive health, we summarize the currently known components of the vaginal virome, its relationship with other constituents of the vaginal microbiota and its association with adverse health outcomes. While a range of eukaryote-infecting viruses has been described to be present in the female genital tract (FGT), few prokaryote-infecting viruses have been described. Literature suggests that various vaginal viruses interact with vaginal bacterial microbiota and host immunity and that any imbalance thereof may contribute to the risk of adverse reproductive health outcomes, including infertility and adverse birth outcomes. Current limitations of vaginal virome research include experimental and analytical constraints. Considering the vaginal virome may represent the missing link in our understanding of the relationship between FGT bacteria, mucosal immunity, and adverse sexual and reproductive health outcomes, future studies evaluating the vaginal microbiome and its population dynamics holistically will be important for understanding the role of the vaginal virome in balancing health and disease.

show abstract

Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people

Cited by 30 publications

References 32 publications

Hepatitis B Virus Entry into Cells

Hepatitis B Virus Entry into Cells

Biosensing based on field-effect transistors (FET): Recent progress and challenges

The Vaginal Virome—Balancing Female Genital Tract Bacteriome, Mucosal Immunity, and Sexual and Reproductive Health Outcomes?

Contact Info

Product

Resources

About